{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:57:12Z","timestamp":1786366632378,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007290","name":"Obel Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.thromres.2021.03.015","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T06:23:26Z","timestamp":1616307806000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance"],"prefix":"10.1016","volume":"202","author":[{"given":"Th\u00f8ger","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Risom","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Manuela","family":"Teodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2021.03.015_bb0005","doi-asserted-by":"crossref","unstructured":"J.A. Baron, G. Gridley, E. Weiderpass, O. Nyr\u00e9n, M. Linet, Venous thromboembolism and cancer., Lancet (London, England). 351 (1998) 1077\u201380. doi:https:\/\/doi.org\/10.1016\/S0140-6736(97)10018-6.","DOI":"10.1016\/S0140-6736(97)10018-6"},{"key":"10.1016\/j.thromres.2021.03.015_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.seminhematol.2010.11.002","article-title":"Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance","volume":"48","author":"Kristinsson","year":"2011","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0031-1297372","article-title":"Bleeding and thrombosis in multiple myeloma and related plasma cell disorders","volume":"37","author":"Coppola","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0020","doi-asserted-by":"crossref","unstructured":"C.S. Eby, Bleeding and thrombosis risks in plasma cell dyscrasias., Hematology Am. Soc. Hematol. Educ. Program. (2007) 158\u2013164. doi:https:\/\/doi.org\/10.1182\/asheducation-2007.1.158.","DOI":"10.1182\/asheducation-2007.1.158"},{"key":"10.1016\/j.thromres.2021.03.015_bb0025","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.03.015_bb0030","doi-asserted-by":"crossref","unstructured":"S. Sallah, A Husain, J. Wan, P. Vos, N.P. Nguyen, The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance., Ann. Oncol. 15 (2004) 1490\u20131494. doi:https:\/\/doi.org\/10.1093\/annonc\/mdh385.","DOI":"10.1093\/annonc\/mdh385"},{"key":"10.1016\/j.thromres.2021.03.015_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.2010.01539.x","article-title":"Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism","volume":"86","author":"Gregersen","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0040","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.03.015_bb0045","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.thromres.2021.03.015_bb0050","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.thromres.2021.03.015_bb0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2021.03.015_bb0065","doi-asserted-by":"crossref","unstructured":"T. Facon, J.Y. Mary, C. Hulin, L. Benboubker, M. Attal, B. Pegourie, M. Renaud, J.L. Harousseau, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, C. Martin, P. Casassus, J. Jaubert, H. Jardel, C. Doyen, B. Kolb, B. Anglaret, B. Grosbois, I. Yakoub-Agha, C. Mathiot, H. Avet-Loiseau, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial, Lancet. 370 (2007) 1209\u20131218. doi:https:\/\/doi.org\/10.1016\/S0140-6736(07)61537-2.","DOI":"10.1016\/S0140-6736(07)61537-2"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2021.03.015_bb0070","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1179\/102453312X13336169156933","article-title":"Thrombosis in multiple myeloma (MM)","volume":"17","author":"Cesarman-Maus","year":"2012","journal-title":"Hematology."},{"key":"10.1016\/j.thromres.2021.03.015_bb0075","doi-asserted-by":"crossref","unstructured":"M. Zangari, L. Fink, F. Zhan, G. Tricot, Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens, Clin. Lymphoma, Myeloma Leuk. 11 (2011) 228\u2013236. doi:https:\/\/doi.org\/10.1016\/j.clml.2011.03.006.","DOI":"10.1016\/j.clml.2011.03.006"},{"key":"10.1016\/j.thromres.2021.03.015_bb0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.thromres.2021.03.015_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","article-title":"The blood coagulation mechanism in multiple myeloma","volume":"29","author":"Zangari","year":"2003","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0090","doi-asserted-by":"crossref","unstructured":"M. Zangari, F. Sagha, E. Anaissie, A. Badros, R. Desikan, A. Fassas, P. Mehta, C. Morris, A. Toor, D. Whit, E. Siegel, B. Barlogie, L. Fink, G. Tricot, Activated protein C resistance in the absence of factor V Leiden mutation is a common \u00ae nding in multiple myeloma and is associated with an increased risk of thrombotic complications, 13 (2002) 187\u2013192.","DOI":"10.1097\/00001721-200204000-00003"},{"key":"10.1016\/j.thromres.2021.03.015_bb0095","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.thromres.2021.03.015_bb0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0105","first-page":"493","article-title":"In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide","volume":"121","author":"Elalamy","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2021.03.015_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH10-03-0187","article-title":"Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma","volume":"105","author":"Auwerda","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210835","article-title":"Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma","volume":"14","author":"Nielsen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2021.03.015_bb0120","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","article-title":"Thrombosis: tangled up in NETs","volume":"123","author":"Martinod","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.03.015_bb0125","doi-asserted-by":"crossref","first-page":"14355","DOI":"10.1007\/s13277-016-5328-z","article-title":"NETs in cancer","volume":"37","author":"Garley","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0130","doi-asserted-by":"crossref","unstructured":"R.A. Sheth, A.H. Jahromi, R. Oklu, H. Albadawi, K.H.K. Wong, Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis, Cardiovasc. Diagn. Ther. 7 (2017) S140\u2013S149. doi:10.21037\/cdt.2017.08.01.","DOI":"10.21037\/cdt.2017.08.01"},{"key":"10.1016\/j.thromres.2021.03.015_bb0135","series-title":"Elevated levels of circulating nucleosomes are not associated with venous thrombosis or neutrophil activation in patients with multiple myeloma, in: 58th ASH Annu","first-page":"274","author":"Lauw","year":"2016"},{"key":"10.1016\/j.thromres.2021.03.015_bb0140","doi-asserted-by":"crossref","unstructured":"S.V. Rajkumar, Updated diagnostic criteria and staging system for multiple myeloma, Am. Soc. Clin. Oncol. Educ. B. 36 (2016) e418\u2013e423. doi:10.14694\/edbk_159009.","DOI":"10.1200\/EDBK_159009"},{"key":"10.1016\/j.thromres.2021.03.015_bb0145","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0150","doi-asserted-by":"crossref","unstructured":"B.G.M. Durie, J.-L. Harousseau, J.S. Miguel, J. Blad\u00e9, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksac, J. Crowley, A. Belch, M. Boccadaro, I. Turesson, D. Joshua, D. Vesole, R. Kyle, R. Alexanian, G. Tricot, M. Attal, G. Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, G. Morgan, S. V Rajkumar, on behalf of the I.M.W. Group, International uniform response criteria for multiple myeloma, Leukemia. 20 (2006) 1467\u20131473. doi:https:\/\/doi.org\/10.1038\/sj.leu.2404284.","DOI":"10.1038\/sj.leu.2404284"},{"key":"10.1016\/j.thromres.2021.03.015_bb0155","doi-asserted-by":"crossref","unstructured":"P. Gimsing, M.O. Holmstr\u00f6m, T.W. Klausen, N.F. Andersen, H. Gregersen, R.S. Pedersen, T. Plesner, P.T. Pedersen, M. Frederiksen, U. Fr\u00f8lund, C. Helleberg, A. Vangsted, P. de Nully Brown, N. Abildgaard, The Danish National Multiple Myeloma Registry., Clin. Epidemiol. 8 (2016) 583\u2013587. doi:https:\/\/doi.org\/10.2147\/CLEP.S99463.","DOI":"10.2147\/CLEP.S99463"},{"key":"10.1016\/j.thromres.2021.03.015_bb0160","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer."},{"key":"10.1016\/j.thromres.2021.03.015_bb0165","first-page":"137","article-title":"Standardization of pre-analytical variables in plasma microparticle microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop","volume":"150","author":"Lacroix","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0170","doi-asserted-by":"crossref","unstructured":"H.C. Hemker, P. Giesen, R. AlDieri, V. Regnault, E. de Smed, R. Wagenvoord, T. Lecompte, S. B\u00e9guin, The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability., Pathophysiol. Haemost. Thromb. 32 (2002) 249\u201353. doi:73575.","DOI":"10.1159\/000073575"},{"key":"10.1016\/j.thromres.2021.03.015_bb0175","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ijlh.12800","article-title":"Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis","volume":"40","author":"Lee","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2021.03.015_bb0180","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1538-7836.2009.03448.x","article-title":"Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice","volume":"7","author":"Wang","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/jth.12503","article-title":"Contact activation: important to consider when measuring the contribution of tissue factor-bearing microparticles to thrombin generation using phospholipid-containing reagents","volume":"12","author":"Bokn\u00e4s","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.015_bb0190","doi-asserted-by":"crossref","unstructured":"M. Demers, D.D. Wagner, Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression, Oncoimmunology. 2 (2013). doi:https:\/\/doi.org\/10.4161\/onci.22946.","DOI":"10.4161\/onci.22946"},{"key":"10.1016\/j.thromres.2021.03.015_bb0195","doi-asserted-by":"crossref","unstructured":"M.P. Crowely, S. Quinn, E. Coleman, J. A. Eustace, O.M. Gilligan, S.I.O. Shea, Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma, J. Thromb. Thrombolysis. 39 (2014) 245\u2013249. doi:https:\/\/doi.org\/10.1007\/s11239-014-1140-z.","DOI":"10.1007\/s11239-014-1140-z"},{"key":"10.1016\/j.thromres.2021.03.015_bb0200","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/10428194.2016.1219900","article-title":"Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma","volume":"58","author":"Tiong","year":"2017","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.thromres.2021.03.015_bb0205","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1076029617715116","article-title":"Graft product for autologous peripheral blood stem cell transplantation enhances thrombin generation and expresses procoagulant microparticles and tissue factor","volume":"24","author":"Sidibe","year":"2018","journal-title":"Clin. Appl. Thromb."},{"key":"10.1016\/j.thromres.2021.03.015_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.thromres.2021.03.015_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/rth2.12161","article-title":"Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: an observational cohort study","volume":"3","author":"Chalayer","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821001067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821001067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:45:42Z","timestamp":1758735942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":43,"alternative-id":["S0049384821001067"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.03.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}